DE3772498D1 - Phospholipidpartikeln mit eingeschlossenen polyen-antibiotika zur behandlung von systemischen pilzinfektionen. - Google Patents

Phospholipidpartikeln mit eingeschlossenen polyen-antibiotika zur behandlung von systemischen pilzinfektionen.

Info

Publication number: DE3772498D1
Authority: DE; Germany
Prior art keywords: antibiotics; infections; vesicles; polyan; mushroom
Prior art date: 1986-08-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE8787307221T

Other languages

English (en)

Inventor

Jill Adler-Moore

Ronald Carl Gamble

Richard Thomas Proffitt

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nexstar Pharmaceuticals Inc

Original Assignee

Vestar Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-21

Filing date

1987-08-14

Publication date

1991-10-02

1987-08-14 Application filed by Vestar Inc filed Critical Vestar Inc

1991-10-02 Application granted granted Critical

1991-10-02 Publication of DE3772498D1 publication Critical patent/DE3772498D1/de

2007-08-15 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000002245 particle Substances 0.000 title abstract 3
230000009885 systemic effect Effects 0.000 title abstract 3
239000003242 anti bacterial agent Substances 0.000 title abstract 2
229940088710 antibiotic agent Drugs 0.000 title abstract 2
150000003904 phospholipids Chemical class 0.000 title abstract 2
235000001674 Agaricus brunnescens Nutrition 0.000 title 1
208000015181 infectious disease Diseases 0.000 title 1
230000000843 anti-fungal effect Effects 0.000 abstract 3
229940121375 antifungal agent Drugs 0.000 abstract 3
206010017533 Fungal infection Diseases 0.000 abstract 2
208000031888 Mycoses Diseases 0.000 abstract 2
230000003115 biocidal effect Effects 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
150000004291 polyenes Chemical class 0.000 abstract 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
239000007983 Tris buffer Substances 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
229960003942 amphotericin b Drugs 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229960000988 nystatin Drugs 0.000 abstract 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Dispersion Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Biophysics (AREA)
Crystallography & Structural Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE8787307221T 1986-08-21 1987-08-14 Phospholipidpartikeln mit eingeschlossenen polyen-antibiotika zur behandlung von systemischen pilzinfektionen. Expired - Lifetime DE3772498D1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US89906486A	1986-08-21	1986-08-21

Publications (1)

Publication Number	Publication Date
DE3772498D1 true DE3772498D1 (de)	1991-10-02

Family

ID=25410437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE8787307221T Expired - Lifetime DE3772498D1 (de)	1986-08-21	1987-08-14	Phospholipidpartikeln mit eingeschlossenen polyen-antibiotika zur behandlung von systemischen pilzinfektionen.

Country Status (14)

Country	Link
US (1)	US5874104A (de)
EP (1)	EP0260811B1 (de)
JP (1)	JPH0615475B2 (de)
KR (1)	KR950013747B1 (de)
AT (1)	ATE66597T1 (de)
AU (1)	AU606880B2 (de)
CA (1)	CA1292184C (de)
DE (1)	DE3772498D1 (de)
DK (1)	DK168982B1 (de)
ES (1)	ES2051740T3 (de)
GR (1)	GR3002852T3 (de)
HK (1)	HK115393A (de)
IE (1)	IE60901B1 (de)
NO (1)	NO174833C (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1338736C (fr) *	1986-12-05	1996-11-26	Roger Baurain	Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2620028B2 (fr) *	1986-12-05	1994-02-25	Ire Celltarg Sa	Procede de preparation de microcristaux comportant a titre de substance active, notamment de l'amphotericine b, microcristaux obtenus et composition pharmaceutique en comprenant
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin
US5616334A (en) *	1987-03-05	1997-04-01	The Liposome Company, Inc.	Low toxicity drug-lipid systems
US6406713B1 (en)	1987-03-05	2002-06-18	The Liposome Company, Inc.	Methods of preparing low-toxicity drug-lipid complexes
CA1338702C (en) *	1987-03-05	1996-11-12	Lawrence D. Mayer	High drug:lipid formulations of liposomal- antineoplastic agents
US4999199A (en) *	1988-11-10	1991-03-12	Board Of Regents, The University Of Texas System	Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics
DE69027941T2 (de) *	1989-11-27	1997-01-23	Nippon Shinyaku Co Ltd	Fettemulsion
WO1992011841A1 (en) *	1991-01-14	1992-07-23	Board Of Regents, The University Of Texas	Anti-hiv activity of liposomal nystatin and amphotericin b
WO1993007884A1 (fr) *	1991-10-25	1993-04-29	Senju Pharmaceutical Co., Ltd.	Preparation externe de traitement de maladies hemorroidaires
JP2915296B2 (ja) *	1993-08-30	1999-07-05	宇野潤	抗真菌製剤
GB9519654D0 (en) *	1995-09-27	1995-11-29	Nycomed Imaging As	Stabilised phospholipid compositions
IL124676A0 (en)	1996-01-25	1998-12-06	Schering Ag	Improved concentrated injection and infusion solutions for intravenous use
GB9721901D0 (en) *	1997-10-16	1997-12-17	Univ Manchester	Particles
WO1999027940A1 (en) *	1997-12-01	1999-06-10	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Formulations for topical treatment of skin infections
IT1301807B1 (it) *	1998-06-25	2000-07-07	Tiberio Bruzzese	Formulazioni farmaceutiche iniettabili di derivati della partricina.
US6613352B2 (en)	1999-04-13	2003-09-02	Universite De Montreal	Low-rigidity liposomal formulation
US6413537B1 (en)	2000-03-10	2002-07-02	Wisconsin Alumni Research Foundation	Nystatin formulation having reduced toxicity
JP4786041B2 (ja) *	2001-03-02	2011-10-05	丸善製薬株式会社	渋味、収斂味を低減する方法および渋味、収斂味低減ハス胚芽抽出物製剤
US7651689B2 (en) *	2002-11-15	2010-01-26	Albert Einstein College Of Medicine Of Yeshiva University	Methods of applying ionization radiation for therapy of infections
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
WO2007038619A2 (en) *	2005-09-27	2007-04-05	Amunix, Inc.	Proteinaceous pharmaceuticals and uses thereof
US7855279B2 (en) *	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
TWI435729B (zh)	2005-11-09	2014-05-01	Combinatorx Inc	治療病症之方法，組合物及套組
EP2918283B1 (de)	2005-12-30	2018-01-31	Zensun (Shanghai) Science & Technology, Co., Ltd.	Verlängerte Freisetzung von Neuregulin für verbesserte Herzfunktion
US8933197B2 (en) *	2007-08-15	2015-01-13	Amunix Operating Inc.	Compositions comprising modified biologically active polypeptides
EP2564857B1 (de)	2008-03-06	2017-05-03	Anacor Pharmaceuticals, Inc.	Boronhaltige Kleinmoleküle als entzündungshemmende Wirkstoffe
JP5843357B2 (ja)	2009-02-03	2016-01-13	アムニクスオペレーティングインコーポレイテッド	延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
NZ596778A (en)	2009-06-08	2013-11-29	Amunix Operating Inc	Glucose-regulating polypeptides and methods of making and using same
EP3278813A1 (de)	2009-06-08	2018-02-07	Amunix Operating Inc.	Wachstumshormonpolypeptide sowie verfahren zur herstellung und verwendung davon
JP6205133B2 (ja)	2009-07-10	2017-09-27	プレジデントアンドフェローズオブハーバードカレッジ	抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
JP2013502458A (ja)	2009-08-24	2013-01-24	アムニクスオペレーティングインコーポレイテッド	凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
CN106361696B (zh) *	2009-10-16	2020-10-23	莱富凯尔创新私人有限公司	用于治疗真菌感染的含胆固醇的脂质体两性霉素的制剂
AU2010313456A1 (en)	2009-10-30	2012-05-17	Ntf Therapeutics, Inc.	Improved neurturin molecules
US20130109674A1 (en)	2009-12-18	2013-05-02	Achelios Therapeutics Llc	Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
WO2011094450A1 (en)	2010-01-27	2011-08-04	Anacor Pharmaceuticals, Inc	Boron-containing small molecules
WO2012066896A1 (ja) *	2010-11-19	2012-05-24	Kato Junji	組合わせ医薬製剤
MX369862B (es)	2012-02-15	2019-11-25	Bioverativ Therapeutics Inc	Composiciones del factor viii y metodos para hacerlas y usarlas.
JP6383666B2 (ja)	2012-02-15	2018-08-29	バイオベラティブセラピューティクスインコーポレイテッド	組換え第ｖｉｉｉ因子タンパク質
HUE037849T2 (hu)	2012-06-08	2018-09-28	Alkermes Pharma Ireland Ltd	Cirkuláris permutációval módosított ligandumok agonistaként és antagonistaként
TWI667255B (zh)	2013-08-14	2019-08-01	美商生物化學醫療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SG10201808315UA (en)	2014-03-25	2018-10-30	The Government Of The Us Secretary Of The Army	Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
EP3226972A4 (de)	2014-12-01	2018-08-08	Achelios Therapeutics, Inc.	Verfahren und zusammensetzungen zur behandlung von migräne und leiden in zusammenhang mit schmerzen
IL257231B (en)	2015-08-03	2022-09-01	Bioverativ Therapeutics Inc	Factor ix fusion proteins and methods of making and using same
CN108348774A (zh)	2015-08-03	2018-07-31	哈佛大学校长及研究员协会	带电离子通道阻断剂及其应用
JP6900385B2 (ja)	2015-11-06	2021-07-07	アジュバンス・テクノロジーズ・インコーポレーテッド	トリテルペンサポニン類似物
WO2018035380A1 (en)	2016-08-17	2018-02-22	Solstice Biologics, Ltd.	Polynucleotide constructs
CN110520150A (zh)	2016-12-02	2019-11-29	比奥维拉迪维治疗股份有限公司	使用嵌合凝血因子治疗血友病性关节病的方法
US11597744B2 (en)	2017-06-30	2023-03-07	Sirius Therapeutics, Inc.	Chiral phosphoramidite auxiliaries and methods of their use
AU2018350887A1 (en)	2017-10-16	2020-03-05	Adjuvance Technologies, Inc.	Triterpene saponin analogues
LT3793588T (lt)	2018-05-18	2025-06-25	Bioverativ Therapeutics Inc.	Hemofilijos a gydymo būdai
US10780083B1 (en)	2019-03-11	2020-09-22	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
WO2020185881A1 (en)	2019-03-11	2020-09-17	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
MX2021010869A (es)	2019-03-11	2022-01-19	Nocion Therapeutics Inc	Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
US11377422B2 (en)	2019-03-11	2022-07-05	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
US10828287B2 (en)	2019-03-11	2020-11-10	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
US20220307013A1 (en)	2019-08-30	2022-09-29	The Regents Of The University Of California	Gene fragment overexpression screening methodologies, and uses thereof
US10933055B1 (en)	2019-11-06	2021-03-02	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
CN114828845A (zh)	2019-11-06	2022-07-29	诺西恩医疗公司	带电的离子通道阻滞剂及其使用方法
US12162851B2 (en)	2020-03-11	2024-12-10	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
KR20230022830A (ko)	2020-03-11	2023-02-16	녹시온 테라퓨틱스 인코포레이티드	하전된 이온 채널 차단제 및 사용 방법
AU2021297984C1 (en)	2020-06-25	2025-12-11	Amunix Pharmaceuticals, Inc.	HER-2 targeted bispecific compositions and methods for making and using the same
KR20230160294A (ko)	2021-03-24	2023-11-23	알케르메스, 인코포레이티드	Upar 항체 및 이를 갖는 융합 단백질
AU2023235562A1 (en)	2022-03-14	2024-08-22	Pfizer Inc.	Methods for producing an adjuvant
AU2023238751A1 (en)	2022-03-21	2024-10-31	Cystetic Medicines, Inc.	Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin b
WO2024116096A1 (en)	2022-12-01	2024-06-06	Pfizer Inc.	Pneumococcal conjugate vaccine formulations
WO2025057058A1 (en)	2023-09-13	2025-03-20	Pfizer Inc.	Methods for producing an adjuvant
WO2025191415A1 (en)	2024-03-11	2025-09-18	Pfizer Inc.	Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4310505A (en) *	1979-11-08	1982-01-12	California Institute Of Technology	Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4497791A (en) *	1983-02-10	1985-02-05	Vestar Research Incorporated	Method for labeling phagocytic cells
GB2135647A (en) *	1983-02-15	1984-09-05	Squibb & Sons Inc	Method of preparing liposomes and products produced thereby
PT78628B (en) *	1984-05-02	1986-06-18	Liposome Co Inc	Pharmaceutical composition with reduced toxicity
US4880635B1 (en) *	1984-08-08	1996-07-02	Liposome Company	Dehydrated liposomes
DK482685D0 (da) *	1984-10-22	1985-10-21	Hope Nat Medical Center	Fremgangsmaade til tilfoersel af micellulaere partikler, der indkapslerbilleddannende og kemoterapeutiske midler, til tumorer i et legeme
US4753788A (en) *	1985-01-31	1988-06-28	Vestar Research Inc.	Method for preparing small vesicles using microemulsification
US4766046A (en) *	1985-09-27	1988-08-23	Liposome Technology, Inc.	Stabilized liposome/amphotericin composition and method
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin

1987
- 1987-08-11 IE IE214887A patent/IE60901B1/en not_active IP Right Cessation
- 1987-08-14 EP EP87307221A patent/EP0260811B1/de not_active Expired - Lifetime
- 1987-08-14 ES ES87307221T patent/ES2051740T3/es not_active Expired - Lifetime
- 1987-08-14 AT AT87307221T patent/ATE66597T1/de not_active IP Right Cessation
- 1987-08-14 DE DE8787307221T patent/DE3772498D1/de not_active Expired - Lifetime
- 1987-08-18 AU AU77160/87A patent/AU606880B2/en not_active Expired
- 1987-08-19 NO NO873492A patent/NO174833C/no not_active IP Right Cessation
- 1987-08-19 CA CA000544830A patent/CA1292184C/en not_active Expired - Lifetime
- 1987-08-20 KR KR1019870009101A patent/KR950013747B1/ko not_active Expired - Lifetime
- 1987-08-20 DK DK434187A patent/DK168982B1/da not_active IP Right Cessation
- 1987-08-21 JP JP62208049A patent/JPH0615475B2/ja not_active Expired - Fee Related
1991
- 1991-10-08 GR GR91401494T patent/GR3002852T3/el unknown
1993
- 1993-10-28 HK HK1153/93A patent/HK115393A/en not_active IP Right Cessation
1995
- 1995-06-06 US US08/467,864 patent/US5874104A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0260811A2 (de)	1988-03-23
EP0260811A3 (en)	1988-07-20
ATE66597T1 (de)	1991-09-15
GR3002852T3 (en)	1993-01-25
ES2051740T3 (es)	1994-07-01
DK434187A (da)	1988-02-22
US5874104A (en)	1999-02-23
NO174833B (no)	1994-04-11
KR950013747B1 (ko)	1995-11-15
JPH0615475B2 (ja)	1994-03-02
IE872148L (en)	1988-02-21
KR880002531A (ko)	1988-05-09
AU7716087A (en)	1988-02-25
NO873492L (no)	1988-02-22
IE60901B1 (en)	1994-08-24
DK168982B1 (da)	1994-07-25
NO174833C (no)	1994-07-20
JPS6366123A (ja)	1988-03-24
HK115393A (en)	1993-11-05
DK434187D0 (da)	1987-08-20
NO873492D0 (no)	1987-08-19
CA1292184C (en)	1991-11-19
EP0260811B1 (de)	1991-08-28
AU606880B2 (en)	1991-02-21

Publication	Publication Date	Title
DE3772498D1 (de)	1991-10-02	Phospholipidpartikeln mit eingeschlossenen polyen-antibiotika zur behandlung von systemischen pilzinfektionen.
AU587232B2 (en)	1989-08-10	Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles and methods for using same for tumor therapy
AU8141791A (en)	1991-11-07	Method for determining unentrapped ionizable bioactive agents in liposome preparations
FI902249A0 (fi)	1990-05-04	Foerfarande foer framstaellning av liposomer med foerbaettrad stabilitet under torkning.
EP0451215A4 (en)	1991-11-13	Pulmonary administration of pharmaceutically active substances
ATE186835T1 (de)	1999-12-15	Herstellung von formulierungen zur arzneiverabreichung mittels elektrotransport
NO180147C (no)	1997-02-26	Fremgangsmåte for fremstilling av HDLC eller et liposom innbefattende et polyen-antisopp-antibiotikum og et lipid
DK32388A (da)	1988-07-28	Phospholipid-baeremiddel for vand-uoploeselige aktive bestanddele
ATE86104T1 (de)	1993-03-15	Mehrstufen-einkapselungs/ladeverfahren zur herstellung von lipophile heilmittel enthaltenden liposomen.

Legal Events

Date	Code	Title	Description
1992-09-24	8364	No opposition during term of opposition
1997-04-30	8327	Change in the person/name/address of the patent owner	Owner name: NEXSTAR PHARMACEUTICALS INC. (N.D.GES.D. STAATES D